EXPAREL®: Long-lasting postsurgical pain control

Set a Smooth Recovery in Motion with EXPAREL®

Reduce the need for opioids while providing long-lasting postsurgical pain control…all from a single dose

Learn More about EXPAREL
DepoFoam® - a unique delivery system for EXPAREL®

Cutting-edge Technology Sets EXPAREL® Apart

With a unique drug delivery system, EXPAREL is designed to extend postsurgical analgesia

Learn More about DepoFoam

The clinical benefit of the attendant decrease in opioid consumption was not demonstrated.

A smooth start to recovery begins with EXPAREL

EXPAREL (bupivacaine liposome injectable suspension) is a liposome injection of bupivacaine, an amide-type local anesthetic, indicated (bupivacaine liposome injectable suspension) for administration into the surgical site to produce postsurgical analgesia.

  • Indicated for single-dose administration into the surgical site to produce postsurgical analgesia
  • DepoFoam® drug delivery system slowly delivers bupivacaine over time to extend the pharmacologic effect of EXPAREL2,3
  • Significantly reduces opioid consumption4,5
  • Eliminates the need for catheters and pumps that may hinder recovery4,6,7-12
  • Safety and tolerability profile similar to placebo

If You Are a Patient

Visit the EXPAREL Patient Site for resources to help before and after surgery.


Is EXPAREL Right for My Patients?

Learn the types of patients and procedures that may benefit from EXPAREL.


Video About DepoFoam®

Watch this short animation to see how EXPAREL uses DepoFoam.


Important Notice

This site is for informational purposes only and is intended to address medical questions from healthcare professionals in the United States.

To report an adverse event, e-mail or dial 1-855-RX-EXPAREL (1-855-793-9727).

For medical inquiries related to EXPAREL, submit a request to Medical Information or call 1-855-RX-EXPAREL (1-855-793-9727).

These are not all of the potential important safety considerations for EXPAREL; please see the full Prescribing Information.


  1. Data on file. Parsippany, NJ: Pacira Pharmaceuticals, Inc.; February 2015.
  2. How DepoFoam® works. Pacira Pharmaceuticals, Inc. website. Accessed January 8, 2015.
  3. Bramlett K, Onel E, Viscusi ER, Jones K. A randomized, double-blind, dose-ranging study comparing wound infiltration of DepoFoam bupivacaine, an extended-release liposomal bupivacaine, to bupivacaine HCl for postsurgical analgesia in total knee arthroplasty. Knee. 2012;19(5):530-536.
  4. Gorfine SR, Onel E, Patou G, Krivokapic Z. Bupivacaine extended-release liposome injection for prolonged postsurgical analgesia in patients undergoing hemorrhoidectomy: a multicenter, randomized, double-blind, placebo-controlled trial. Dis Colon Rectum. 2011;54:1552-1559.
  5. Golf M, Daniels SE, Onel E. A phase 3, randomized, placebocontrolled trial of DepoFoam® bupivacaine (extended-release bupivacaine local analgesic) in bunionectomy. Adv Ther. 2011;28(9):776-788.
  6. Kessler ER, Shah M, Gruschkus SK, Raju A. Cost and quality implications of opioid-based postsurgical pain control using administrative claims data from a large health system: opioid-related adverse events and their impact on clinical and economic outcomes. Pharmacotherapy. 2013;33(4):383-391.
  7. Ilfeld BM, Loland VJ, Sandhu NS, Suresh PJ, Bishop MJ, Donohue MC. Continuous femoral nerve blocks: the impact of catheter tip location relative to the femoral nerve (anterior versus posterior) on quadriceps weakness and cutaneous sensory block. Anesth Analg. 2012;115(3):721-727.
  8. Kinder R, Hsiung R. Overview of peripheral nerve blocks. In: Chu LF, Fuller A, eds. Manual of Clinical Anesthesiology. 1st ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2011. Accessed October 7, 2014.
  9. Process for handling elastomeric pain relief balls (ON-Q PainBuster and others) requires safety improvements. Institute for Safe Medication Practices website. Accessed June 19, 2014.
  10. I-Flow ON-Q pump with ONDEMAND bolus button. US Food and Drug Administration website. Accessed January 5, 2015.
  11. Continuous peripheral nerve blocks in outpatients. NYSORA–The New York School of Regional Anesthesia website. foundations-of-ra/3055-continuous-peripheral-nerve-blocks-in-outpatients.html. Accessed January 5, 2015.
  12. Frost & Sullivan. New opportunities for hospitals to improve economic efficiency and patient outcomes: the case of EXPAREL™, a long-acting, non-opioid local analgesic. Accessed January 5, 2015.

Important Safety Information

Important Safety Information

Medical Information

US healthcare professionals Click Here

Non-US healthcare professionals can submit a request to

If you are not a healthcare professional, please discuss any questions you have regarding your health or treatment with your physician, pharmacist, nurse, or other healthcare professional.

Important new information about EXPAREL®

The FDA confirms that EXPAREL has always been approved for "administration into the surgical site to produce postsurgical analgesia" for use in a variety of surgeries not limited to those studied in its pivotal trials.

"We are pleased to announce a successful collaboration with the FDA to resolve this matter in an expeditious and meaningful way that allows us to get back to the important task at hand—reducing postsurgical opioid exposure by providing a non-opioid option like EXPAREL to as many patients as appropriate."

- Dave Stack, Chief Executive Officer and Chairman of Pacira

The clinical benefit of the decrease in opioid consumption was not demonstrated in the pivotal trials.

Important Safety Information

  • EXPAREL is contraindicated in obstetrical paracervical block anesthesia
  • EXPAREL has not been studied for use in patients younger than 18 years of age
  • Non-bupivacaine-based local anesthetics, including lidocaine, may cause an immediate release of bupivacaine from EXPAREL if administered together locally. The administration of EXPAREL may follow the administration of lidocaine after a delay of 20 minutes or more. Formulations of bupivacaine other than EXPAREL should not be administered within 96 hours following administration of EXPAREL
  • Monitoring of cardiovascular and neurological status as well as vital signs should be performed during and after injection of EXPAREL as with other local anesthetic products
  • Because amide-type local anesthetics, such as bupivacaine, are metabolized by the liver, EXPAREL should be used cautiously in patients with hepatic disease. Patients with severe hepatic disease, because of their inability to metabolize local anesthetics normally, are at a greater risk of developing toxic plasma concentrations
  • In clinical trials, the most common adverse reactions (incidence ≥10%) following EXPAREL administration were nausea, constipation, and vomiting

Please see the full Prescribing Information for EXPAREL.

EXPAREL® (bupivacaine liposome injectable suspension) Sign Up

Sign up to receive updates on EXPAREL.

Providing the optional information about you below enables us to provide information geared to your needs.
Yes, I would like to receive periodic updates about EXPAREL via e-mail. I agree to the Privacy Policy

Thank you! Your registration is complete.

Sorry. There was an error submitting your request. Please try again at another time.

Sorry. The connection to the server was lost. Please try again at another time.